Physician profile
Ray Allen
NPI 1295702595
$9,683.00
in general payments reported to CMS, 2019-2025
40 companies · $1,835 in 2025
The $1,835 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,662 · 2020: $189 · 2021: $746 · 2022: $1,446 · 2023: $1,859 · 2024: $1,946 · 2025: $1,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,629 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,628.78 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,563.50 | 2019-2025 | |
| Pfizer INC. | $1,066.40 | 2019-2025 | |
| Amgen INC. | $899.43 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $781.73 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Philips North America LLC | $659.16 | 2022-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
| E.R. Squibb & Sons, L.L.C. | $594.12 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $554.51 | 2019-2025 | Jardiance |
| Medtronic, INC. | $537.89 | 2021-2025 | Onyx Frontier, Symplicity G3 |
| Merck Sharp & Dohme LLC | $337.35 | 2021-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $304.13 | 2019-2025 | Farxiga, Wainua |
| Boston Scientific Corporation | $238.67 | 2019-2025 | Watchman Flx |
| Daiichi Sankyo INC. | $231.88 | 2023-2025 | Injectafer |
| Janssen Pharmaceuticals, INC | $228.13 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $223.36 | 2024-2025 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $180.45 | 2019-2023 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $176.99 | 2019-2024 | Evkeeza |
| Terumo Medical Corporation | $125.08 | 2019-2023 | Glidewire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.73 | 2020-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $93.30 | 2025 | |
| Novo Nordisk INC | $92.34 | 2024-2025 | Wegovy |
| Cordis US Corp. | $81.71 | 2025 | Mynx Control |
| Chiesi USA, INC. | $61.42 | 2019-2023 | Kengreal |
| Irhythm Technologies, INC. | $52.21 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Scpharmaceuticals INC. | $50.21 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $45.69 | 2024 | Arcalyst |
| Lundbeck LLC | $43.30 | 2019 | |
| Biotronik INC. | $41.06 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $39.81 | 2023 | Inpefa |
| Esperion Therapeutics, INC. | $39.05 | 2021-2025 | Nexletol |
| Abiomed | $35.74 | 2024 | Impella |
| Cvrx, INC. | $28.76 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $28.32 | 2022-2023 | Livalo |
| Abbott Laboratories | $24.16 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Csl Behring | $22.77 | 2022 | |
| Vifor Pharma, INC. | $19.70 | 2019 | |
| Angiodynamics, INC. | $19.69 | 2025 | Auryon Laser System 100-120 Vac |
| Kiniksa Pharmaceuticals, LTD. | $18.90 | 2022 | |
| Akcea Therapeutics, INC. | $18.74 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.46 | 2019 | |
| G Medical Diagnostic Services, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.